Healthcare

We create and invest in leading companies in therapeutics, medtech, and health IT & services.

Thirty three products and drugs approved

With another 12 drugs in phase 3. Typically, only 1 in 5,000 drugs makes it from idea to market.

Thirty one companies created from scratch

If we can't find a company solving an important problem, we create one ourselves - just like we did with Innovent, Denali, Beam and Prime Medicine to name a few.

$3.5B

Over three and a half billion dollars over eleven funds

Without the pressure of fundraising from outside investors, we're privileged to champion companies that help heal the world.

Atalanta

Opening new frontiers toward the treatment of neurodegenerative diseases and other neurological disorders.

Achieving broad distribution of RNAi therapeutics throughout the CNS has been a limitation in developing effective medicines for neurodegenerative diseases.

AviadoBio

Pioneering genetic therapies for neurodegenerative disease

Neurological disease remains the largest cause of disability and second leading cause of mortality, worldwide, but life-changing therapies could be on the horizon.

CHARM Therapeutics

CHARM Therapeutics: Unfolding a new era of drug discovery by leveraging breakthrough 3D deep learning technology.

Predicting the structure and nature of protein-ligand interactions could enable a revolution in virtual screening potentially addressing difficult-to-drug molecular targets.

Denali Therapeutics

Neurodegenerative disease has remained an undefeated adversary for too long.

That needed to change. Through our affiliate FBRI, F-Prime has had a long-standing commitment to cure neurodegenerative diseases. But all previous disease-modifying trials in this arena had failed. In the past decade, though, major scientific insights into the underlying genetic causes and biological processes—along with new translational medicine tools—gave us hope for a different future.

Equip

Gold-standard eating disorder treatment delivers lasting recovery for patients and families at home.

In 2019, Kristina Saffran and Dr. Erin Parks came to us with a slide deck and a passion for helping those struggling with eating disorders (EDs).

K36 Therapeutics

K36 Therapeutics: Advancing a first-in-class MMSET inhibitor to benefit t(4;14) multiple myeloma patients and beyond.

F-Prime has long been interested in precision medicine approaches that tackle the underlying cause of diseases, ranging from investments in small molecules (e.g., Blueprint Medicines) to gene editing technologies (e.g., Beam Therapeutics).

Orchard Therapeutics

Prof. Bobby Gaspar wanted to solve a big puzzle.

But he only had a few pieces in hand. He and his co-founders had some of the most exciting-edge gene therapy medicines-and clinical data showing they worked-but that wasn't enough.

PatientPing

Patients get care from many providers. When these caregivers don’t coordinate, it’s dangerous and expensive.

Could this be improved by solving a communication problem?

Peptone

Peptone: Bringing computational design to antibody drug discovery.

Many human proteins are intrinsically disordered and play a critical role in key biological processes — predicting their behaviour could unlock therapeutics acting at new high-value targets.

Prime Medicine

Prime Medicine: Advancing a next-generation gene editing technology

Using “search and replace” to address the fundamental causes of genetic disease.

Project Beacon

As COVID-19 rapidly spread across the Commonwealth of Massachusetts, it quickly grew apparent to Boston’s life science community that there was a dire need for efficient, affordable, accessible and equitable testing.

Boston’s life science community needed efficient, affordable, accessible and equitable testing.

Ultragenyx

Emil Kakkis has always been driven to solve difficult problems.

When he approached us, he was looking for an investor who would understand rare diseases the way he did. His vision was to build a mission-driven company to treat rare and ultra-rare genetic diseases—all the way from concept to globally-approved drugs.

The list includes investments made by funds managed by F-Prime. The companies are listed in alphabetical order. The list of investments is updated quarterly and, as such, may not reflect most recent F-Prime investments. This list also excludes companies that are currently in stealth.